Australian Market Access Study Shows Why In-Person Networking Still Defines HealthTech Scale

Sofie Poirier's recent trip leading the Mobility Unlimited Hub (MUH) delegation to Australia provides a compelling case study for founders: while digital tools accelerate early connection, scaling specialized health technologies still requires deep, on-the-ground presence. The primary lesson isn't just about global expansion; it’s about de-risking the crucial final mile of adoption. The MUH cohort’s visit to Melbourne and Sydney wasn't merely a tourism trip—it was an intensely coordinated market intelligence mission. By engaging with diverse bodies like Royal Rehab, MedTechVic’s research hub at Swinburne University, and attending focused events like the Assistive Technology Suppliers Australia Independent Living Expo, the founders built an immediate, multi-threaded pipeline of feedback. This level of targeted exposure to occupational therapists, physiotherapists, clinicians, and academic partners is invaluable. The core engineering ingenuity demonstrated here lies not in a specific piece of software, but in building sophisticated *ecosystem access*. MaRS effectively de-risked the exploratory phase for its ventures. As Sofie highlighted, approaching the market as a united Canadian front amplified their reach far past what individual startups could achieve alone. The value proposition is clear: bypassing months of cold outreach and institutional navigation to secure immediate meetings with decision-makers. The biggest structural insight offered by this trip revolves around reimbursement and implementation feasibility. Comparing Canada and Australia, Sofie noted that while the 'need' for technology exists in both countries, the pathway to actual *implementation* differs dramatically. The Australian system appears to have a more readily available mechanism for adopting new solutions, making direct physical contact with potential distributors and paying stakeholders essential for quick commercialization. This confirms that in complex medical markets, trust—built through face-to-face interaction—is the most critical prerequisite for market entry. **Why this sticks in Canada:** The primary challenge for Canadian health tech is often bureaucratic reimbursement structures that slow adoption despite high clinical enthusiasm. MaRS's model of organized international delegations serves as a highly effective, repeatable playbook to help Canadian founders overcome two hurdles simultaneously: gaining vital international market intelligence and establishing the foundational relationships needed to test their models against different regulatory environments (like Australia’s). This expertise in global 'de-risking' positions maRS not just as an incubator, but as a critical foreign affairs arm for Canadian deep tech.